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Abstract
Primary signet ring cell carcinoma of urinary bladder is a rare type of bladder tumor and carries a very
high mortality rate. It may have a clinical presentation similar to common diseases like benign prostatic
hypertrophy and the management options are extremely limited. We report a case of 58-year-old
Caucasian male who presented with a 5 month history of increased frequency of urination, nocturia
and weight loss without any fever or hematuria. He was found to have an increased creatinine of
2.8 mg/dl and a prostate specific antigen level of 0.18 ng/ml. His azotemia was thought to be secondary
to BPH. A Foley catheter was initially placed with a plan for outpatient follow up. On removal of the
catheter his problems persisted and he returned to the hospital. Diagnostic work up including
abdominal ultrasonography, computed tomography scan, retrograde pyelogram, cystography and
cystoscopic biopsies revealed the diagnosis of primary signet ring cell carcinoma of urinary bladder.
Although cystectomy was planned, our patient passed away before this could be done.
Introduction
Primary signet ring cell carcinoma of urinary bladder is
a rare type of bladder tumor and carries a very high
mortality rate. It may have a clinical presentation and
symptomatology similar to common diseases like benign
prostatic hypertrophy. It is diagnosed with bladder biopsy.
Unfortunately, due to the rarity of this disease entity and
due to the aggressive nature of tumor, the treatment
options are extremely limited.
Case presentation
A 58-year-old previously healthy Caucasian male pre-
sented with a five month history of increased frequency
of urination, feeling of incomplete emptying and
nocturia. He denied any history of fever, hematuria,
nausea, vomiting or diarrhea. He complained of approxi-
mate 10 pound weight loss over a period of 1 week. He
reported a previous diagnosis of enlarged prostate with a
normal prostate specific antigen (PSA). He also reported
a recent history of “small heart attack” for which he was
medically treated at an outlying facility where he was also
informed about poor kidney function. He also gave
history of recently diagnosed hypertension and a 80 pack
year of ongoing smoking. His medications included
amlodipine, finasteride, doxazosin, metoprolol, clopi-
drogel, aspirin and lovastatin. All of these were started
5 days prior to presentation. Physical examination
revealed a healthy appearing male with normal vital
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tender prostate. Rest of the physical exam was unremark-
able. Laboratory data revealed hemoglobin 10.3 g/dl,
blood urea nitrogen 24 mg/dl, creatinine 2.7 mg/dl, and
PSA level 0.18 ng/ml. Urinalysis was negative for RBC’s,
WBC’s, bacteria, or nitrates. Retroperitoneal ultrasound
showed normal sized kidneys with mild pyelocaliectasis
bilaterally, prostate measured 4 × 2.7 × 2.6 cm with
homogenous echotexture, otherwise unremarkable.
Immediately after placement of foley catheter he had
650 ml of urine output. Blood urea nitrogen decreased to
18 mg/dl and serum creatinine decreased to 1.7 mg/dl.
His azotemia was thought to be secondary to BPH and he
was discharged with indwelling foley catheter to be
followed up as an outpatient. At outpatient clinic, on
removal of his foley catheter, his post void residual was
found to be 150 ml. Various management options
including surgical interventions were discussed with the
patient in detail. After discussion patient was discharged
home to be followed up as an outpatient but was started
on tamsulosin. He returned to the hospital with
complaints of urgency and frequency. His creatinine
had increased to 5.0 mg/dl. Abdominal CT at this time
revealed bilateral hydronephrosis and hydroureter. This
finding was confirmed on retrograde pyelogram. Cysto-
graphy showed marked thickening of the urinary bladder
trabeculae. Cystoscopy revealed the entire bladder
mucosa to be thickened and edematous with an
exaggerated granular type appearance and bilateral
uretero-vesical junction stenosis prompting placement
of bilateral ureteral stents. He subsequently had a diuresis
producing 6 liters of urine. This was followed by a
reduction in the serum creatinine from 5.2 to 3.1 mg/dl
over two days. Pathological analysis of tissue from
random bladder wall biopsies at the time of cystoscopy
revealed an infiltrate of cells beneath the surface
epithelium. These cells were described as small, with a
high nuclear-cytoplasmic ratio. Many cells showed a
cytoplasmic vacuolization with displacement of crescen-
tic, hyperchromatic nuclei. Special stain results were
positive for mucin, pan-cytokeratin, CK7 and CK20 but
negative for PSA and PAP (prostatic acid phosphatase).
Based on these results, a diagnosis of Primary Signet Ring
Cell Carcinoma (PSRCC) of the bladder was established.
He underwent esophagogastroduodenoscopy and colo-
noscopy to evaluate possible primary site of his
malignancy but were found to be negative. Management
plans were then made for radical cystectomy. But the
subsequent course was complicated by colitis secondary
to Clostridium difficile requiring total colectomy with
diverting ileostomy. Pathologic evaluation of the
removed colon showed no evidence of malignant
involvement. Recovery was further complicated by
myocardial infarction requiring coronary artery bypass
grafting. The patient failedt or e c o v e ra n dc o n t i n u e dt o
deteriorate. After discussion with family his care was
t r a n s f e r r e dt oh o s p i c ea n dh ep a s s e da w a y .C y s t e c t o m y
was therefore not performed.
Discussion
Primary signet-ring cell carcinoma (PSRCC) is a rare
variation of adenocarcinoma of the urinary bladder.
English literature review on pubmed reveals less than
100 cases reported. Adenocarcinoma constitutes 2% of all
bladder cancers with the majority being metastatic rather
than primary [1]. A study of 713 cases of primary bladder
tumor in Sweden revealed 4 signet ring cell carcinomas,
only 0.6 % [2]. Another series of 715 bladder cancers in
Germany revealed 18 adenocarcinomas but only one with
the classic histologic pattern of signet-ring cell carcinoma
[3]. Signet-ring cells are much more commonly described
in primary adenocarcinoma of the stomach, colon, breast
or gallbladder and malignancies of these organs should be
excluded before diagnosing PSRCC of urinary bladder [3].
A 3:1 male to female predominance has been shown [4],
but in male patients, it is especially necessary to rule out
prostatic adenocarcinoma as a possible site of origin [5].
Most patients present in middle-age with symptoms
indistinguishable from the much more common transi-
tional cell carcinoma of the bladder. The most common
presenting symptoms are hematuria and difficulty in
urination which can be mistaken for a urinary tract
infection. In cases of rapid growth in the trigone area,
oliguria, bladder irritation, and renal failure can be the
initial presenting signs [6] Yamamoto and associates
described one patient, similar to our own, who presented
with renal failure and oliguria without gross hematuria [7]
Cases have also been reported presenting with a palpable
suprapubic mass [8], and one with a palpable supracla-
vicular lymph node [4] The average time from initial
symptoms to the first physician visit has been reported to
be five months [8] but no relationship between the
duration of symptoms before presentation and the stage of
disease has been found [5].
Grignon et al. compared the gross features of 34 cases of
primary signet-ring cell carcinoma. They found that 47.1%
have no mucosal or mass lesion present on cystoscopy.
The most common description is of “edematous mucosa”
but descriptions of erythematous or finely granular
mucosa are also found. As in our case, the bladder wall
is often described as thickened or fibrotic [4]. Signet-ring
cells first invade the mucosa and submucosa of a hollow
organ with eventual full-thickness involvement. This
pattern of invasion can produce extensive lateral spread
without the development of a protruding neoplasm [9],
but in more than half of cases, a definite mass lesion is
found with morphology ranging from polypoid or
pedunculated to sessile to ulcero-infiltrative [4]. Often a
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show diffuse bladder wall thickening [1]. Because this
tumor mainly has an infiltrative rather than exophytic
growth pattern, it is not readily identifiable on cystoscopy.
A full-thickness biopsy of the bladder may be necessary to
make the diagnosis [8]. As in our patient, this diffusely
infiltrating lesion can occlude the ureters early in its course
causing obstruction and hydronephrosis [9].
Signet ring cells are described as crescent shaped cells
containing nuclei compressed to one edge of the cell by
large amounts of cytoplasmic mucin appearing as a single
clear vacuole in some tumors and as a foamy, multi-
vesicular cytoplasmic material in others [4,8] Mucin
accumulations form in the cytoplasm and nuclei are
unevenly distributed [7]. Routine mucin staining of
otherwise normal transitional cell carcinoma will reveal
signet ring cells in many cases and the exact percentage of
signet ring cells that must be present in order to make the
diagnosis of PSRCC of the bladder has not been
established. Holmang and associates suggested that
50-60% of the tumor should be made up of signet-ring
cells to make this classification [2]. However, because the
linitis plastica-like pattern of diffuse signet-ring cell
infiltration is associated with a poorer prognosis, it has
been suggested that only this pattern should be considered
a pure signet-ring cell carcinoma [4]. Bladder tumors
Figure 2. Computerized tomography scan showing urinary
bladder wall thickening.
Figure 1. Computerized tomography scan showing
bilateral hydronephrosis and hydroureter.
Figure 3. Cystogram showing marked trabecular thickening.
Figure 4. Bladder biopsy slide showing normal transitional
epithelium on the left and infiltrative tumor cells on the right.
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a thorough search for a distant primary site. Those
consisting of a mix of signet-ring cells and transitional
cells are more likely to be of primary bladder origin [1].
Also, PSRCC is usually a solitary lesion (63%) in contrast
to transitional cell carcinoma which is most often multi-
focal (66%) [8].
Three theories for the histogenesis of this type of
carcinoma have been suggested in literature. First is the
metaplastic potential of urothelium which may occur
along the surface of the bladder or in areas of cystitis
cystica within the bladder. The second is that diffuse signet
ring cell adenocarcinoma derives from isolated signet ring
cells that exist scattered in normal transitional epithelium.
The third possibility is that of signet ring cell carci-
noma arising from metaplastic transitional cell carcinoma
[4,10-14].
Treatment options for PSRCC are limited. This is a rare
disease entity; no specific chemotherapy has been recom-
mended in the literature. Radiotherapy has also not been
shown to be successful [2]. Total cystectomy with excision
of adjacent tissues may offer some hope in this aggressive
malignancy [8]. There is no specific serum tumor marker
for PSRCC of the bladder, but elevated carcinoembryonic
antigen (CEA) levels have been reported. In cases where
CEA is elevated at diagnosis, levels may be used for post-
operative monitoring [7]. Death is most often the result of
distant metastases. Therefore, the most successfully
reported treatment strategy is resection of the primary
tumor before metastasis occurs [1]. As extensive intra-
mural growth is so often found at diagnosis, total
cystectomy may be the only hope for cure [15]. Kondo
and associates reported no difference in mean remission
rates between patients who received radiotherapy either
pre- or post-operatively and those who did not [8]. In
2001, Yasuhiro and associates described successful treat-
ment of a PSRCC of the bladder with intra-arterial
administration of carboplatin through the left vesicular
artery. Complete remission had been maintained for
44 months at the time of their publication [16].
Unfortunately, this is the only such case reported. This
disease typically carries a poor prognosis, often due to
extensive spread at the time of diagnosis.
Conclusion
PSRCC of urinary bladder is a rare entity with a very poor
prognosis. Since patients may present with clinical picture
similar to common diseases like BPH it may be difficult to
diagnose early in the course of the disease. Treatment
options are extremely limited and not well studied.
Therefore it is important for the clinicians to be aware of
this disease entity.
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